Cargando…

Raloxifene Has No Efficacy in Reducing the High Bone Turnover and the Risk of Spontaneous Vertebral Fractures after Denosumab Discontinuation

At denosumab discontinuation, an antiresorptive agent is prescribed to reduce the high bone turnover, the rapid bone loss, and the risk of spontaneous vertebral fractures. We report the case of a woman treated with aromatase inhibitors and denosumab for 5 years. Raloxifene was then prescribed to pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gonzalez-Rodriguez, Elena, Stoll, Delphine, Lamy, Olivier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166370/ https://www.ncbi.nlm.nih.gov/pubmed/30310704 http://dx.doi.org/10.1155/2018/5432751

Ejemplares similares

Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women
por: Ha, J., et al.
Publicado: (2022)

Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases
por: Burckhardt, Peter, et al.
Publicado: (2021)

ODP119 Raloxifene use after denosumab discontinuation partially attenuates bone loss in the lumbar spine in postmenopausal osteoporosis
por: Hone, Namki, et al.
Publicado: (2022)

Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report
por: Kashii, Masafumi, et al.
Publicado: (2020)

Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases
por: Dupont, Jolan, et al.
Publicado: (2022)

THU448 Multiple Non-traumatic Vertebral Fractures After Discontinuation Of Denosumab
por: Riahi, Shayan, et al.
Publicado: (2023)

Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab
por: Anastasilakis, Athanasios D., et al.
Publicado: (2023)

Effect of risedronate on bone loss at discontinuation of denosumab
por: Laroche, Michel, et al.
Publicado: (2020)

Bone Health and Denosumab Discontinuation in Oncology Populations
por: Cheung, Yee-Ming Melody, et al.
Publicado: (2022)

Commentary to “Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials” (Galvano et al. J Bone Oncol 2019; 18:100252)
por: Gonzalez-Rodriguez, Elena, et al.
Publicado: (2020)

Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses
por: Cosman, Felicia, et al.
Publicado: (2022)

Denosumab Reduces the Incidence of New Vertebral Fractures in Men With Prostate Cancer
por: Silver, David S.
Publicado: (2010)

Denosumab Is Superior to Raloxifene in Lowering Risks of Mortality and Ischemic Stroke in Osteoporotic Women
por: Liu, Ting-Chun, et al.
Publicado: (2023)

Rebound Vertebral Fractures in a Patient With Lung Cancer After Oncology-Dose Denosumab Discontinuation: A Cautionary Tale
por: Tyan, Alexander, et al.
Publicado: (2019)

Effects of the Combination Treatment of Raloxifene and Alendronate on the Biomechanical Properties of Vertebral Bone
por: Diab, Tamim, et al.
Publicado: (2011)

Multiple Spontaneous Vertebral Fractures in a Younger Post-menopausal Woman Upon Stopping Denosumab Therapy
por: Hu, Xun Yang, et al.
Publicado: (2023)

Discontinuation of Denosumab and Associated Fracture Incidence: Analysis From the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial
por: Brown, Jacques P, et al.
Publicado: (2013)

Bone Turnover in Vertebral Fractures: Does it Effect the Decision of Surgery?
por: Ataizi, Zeki Serdar, et al.
Publicado: (2018)

Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation
por: Anastasilakis, Athanasios D., et al.
Publicado: (2020)

Assessment of Strategies for Safe Drug Discontinuation and Transition of Denosumab Treatment in PMO—Insights From a Mechanistic PK/PD Model of Bone Turnover
por: Martínez-Reina, Javier, et al.
Publicado: (2022)

Comparative Adverse Kidney Outcomes in Women Receiving Raloxifene and Denosumab in a Real-World Setting
por: Chen, Hsin-Wei, et al.
Publicado: (2022)

SAT-532 Bisphosphonates Prevent Bone Loss Associated with Denosumab Treatment Discontinuation
por: Zanchetta, Maria Belen, et al.
Publicado: (2019)

Comparison of Effects of Alendronate and Raloxifene on Lumbar Bone Mineral Density, Bone Turnover, and Lipid Metabolism in Elderly Women with Osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2008)

Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation
por: Fu, Qiang, et al.
Publicado: (2023)

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures
por: Austin, Matthew, et al.
Publicado: (2012)

Effects of bone turnover status on the efficacy and safety of denosumab among haemodialysis patients
por: Hori, Mayuko, et al.
Publicado: (2022)

Failure of Oral Risedronate Therapy to Prevent Spontaneous Vertebral Fracture in a Patient Ceasing Denosumab: A Cautionary Case
por: Davidoff, Dahlia F, et al.
Publicado: (2020)

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
por: Sánchez, A., et al.
Publicado: (2016)

Observations following discontinuation of long-term denosumab therapy
por: McClung, M. R., et al.
Publicado: (2017)

Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
por: Anastasilakis, Athanasios D., et al.
Publicado: (2021)

Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation
por: Kim, Albert S., et al.
Publicado: (2022)

Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
por: Adachi, Jonathan D., et al.
Publicado: (2017)

High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis
por: Ishikawa, Koji, et al.
Publicado: (2016)

Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients
por: Kamimura, M., et al.
Publicado: (2016)

Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover
por: Collette, J., et al.
Publicado: (2009)

Kinetic of bone turnover markers after osteoporotic vertebral compression fractures in postmenopausal female
por: Pan, Changyu, et al.
Publicado: (2018)

Changes in Bone Turnover Markers after Osteoporotic Vertebral Compression Fractures in Males and Females
por: Jia, Zhongxiong, et al.
Publicado: (2022)

MON-LB72 Multicentric Carpotarsal Osteolysis Syndrome (MCTO) Has a Generalized High Turnover Bone Phenotype, High S RANKL and Responds to Denosumab
por: Regev, Ravit, et al.
Publicado: (2020)

Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation
por: Jähn-Rickert, Katharina, et al.
Publicado: (2020)

Changes of Bone Turnover Markers and Bone Tissue Content After Severe Osteoporotic Vertebral Compression Fracture
por: Qi, Haoran, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hf99hlbaqqgvss0c4k8p7ornsb